RT Journal Article
SR Electronic
T1 <sup>18</sup>F-DCFPyL PET/CT in Metastatic Renal Cell Carcinoma
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 282
OP 285
DO 10.2967/jnmt.121.262799
VO 50
IS 3
A1 Geoffrey M. Currie
A1 Marko Trifunovic
A1 Jui Liu
A1 Sang Kim
A1 Howard Gurney
YR 2022
UL http://tech.snmjournals.org/content/50/3/282.abstract
AB Targeted molecular imaging with PET uses chemical ligands that are peptides specifically targeting a receptor of interest. Prostate-specific membrane antigen (PSMA) is substantially upregulated in prostate cancer but is also expressed in the neovascular tissue of several malignancies, including renal cell carcinoma (RCC). Radiolabeled peptide targets for PSMA may be helpful in detecting metastatic RCC lesions. We present a case of incidental detection of RCC metastatic disease with PSMA-targeted PET, and we explore potential use for deliberate evaluation of RCC with PSMA-targeted tracers.